Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery

被引：6

作者：

Bachellerie, B. ^{[1
]}

Ruiz, S. ^{[1
]}

Conil, J. -M. ^{[1
]}

Crognier, L. ^{[1
]}

Seguin, T. ^{[1
]}

Georges, B. ^{[1
]}

Fourcade, O. ^{[1
]}

机构：

[1] Hop Rangueil, Pole Anesthesie Reanimat, F-31059 Toulouse 9, France

来源：

ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION | 2014年 / 33卷 / 01期

关键词：

Dabigatran; Overdose; Hemodialysis; Acute renal injury; NONSPECIFIC REVERSAL AGENTS; ORAL ANTICOAGULANTS; RIVAROXABAN;

D O I：

10.1016/j.annfar.2013.11.011

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Dabigatran is a direct thrombin inhibitor indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation. No reversal agent exists, but hemodialysis has been proposed as dabigatran removal method. We report a case of an 80-year-old man presenting hemorrhage with dabigatran overdose caused by obstructive acute renal failure. Before nephrostomy, several hemodialysis sessions were necessary to remove dabigatran probably because of its large volume of distribution. (C) 2013 Societe francaise d'anesthesie et de reanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.

引用

页码：44 / 46

页数：3

共 9 条

[1] The role of the laboratory in treatment with new oral anticoagulants [J].

Baglin, T. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 :122-128

[2] Removal of Dabigatran by Hemodialysis [J].

Chang, Don N. ;

Dager, William E. ;

Chin, Andrew I. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (03) :487-489

[3] Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban [J].

Levi, Marcel .

THROMBOSIS AND HAEMOSTASIS, 2012, 108 (02) :201-202

[4] Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting [J].

Levy, Jerrold H. ;

Faraoni, David ;

Spring, Jenna L. ;

Douketis, James D. ;

Samama, Charles M. .

ANESTHESIOLOGY, 2013, 118 (06) :1466-1474

[5] Pharmacometric Characterization of Dabigatran Hemodialysis [J].

Liesenfeld, Karl-Heinz ;

Staab, Alexander ;

Haertter, Sebastian ;

Formella, Stephan ;

Clemens, Andreas ;

Lehr, Thorsten .

CLINICAL PHARMACOKINETICS, 2013, 52 (06) :453-462

[6] Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban [J].

Marlu, Raphael ;

Hodaj, Enkelejda ;

Paris, Adeline ;

Albaladejo, Pierre ;

Crackowski, Jean Luc ;

Pernod, Gilles .

THROMBOSIS AND HAEMOSTASIS, 2012, 108 (02) :217-224

[7] Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors [J].

Sie, P. ;

Samama, C. -M. ;

Godier, A. ;

Rosencher, N. ;

Steib, A. ;

Llau, J. -V. ;

van der Linden, P. ;

Pernod, G. ;

Lecompte, T. ;

Gouin-Thibault, I. ;

Albaladejo, P. .

ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2011, 30 (09) :645-650

[8]

ten Cate H, 2013, THROMB J, V11, DOI 10.1186/1477-9560-11-8

[9] Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding [J].

Warkentin, Theodore E. ;

Margetts, Peter ;

Connolly, Stuart J. ;

Lamy, Andre ;

Ricci, Chris ;

Eikelboom, John W. .

BLOOD, 2012, 119 (09) :2172-2174

← 1 →